Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2010-02-23
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S333000
Reexamination Certificate
active
07666874
ABSTRACT:
The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome, chronic eosinophilic leukemia and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIP1L1-PDGFRα, TEL-PDGFRβ or similar mutations that activate PDGFR.
REFERENCES:
patent: 7169791 (2007-01-01), Breitenstein et al.
patent: 2004/005281 (2004-01-01), None
patent: 2005/039586 (2005-05-01), None
patent: 2005/049032 (2005-06-01), None
Cross et al., Leukemia, 16, 1207-1212, 2002.
Piccaluga et al., Expert Opinion in Biological Therapy, 7(10), 1597-1611, 2007.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Weisberg et al., “Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl,” Cancer Cell. vol. 7, No. 2, pp. 129-141 (2005).
Giles et al., “A phase IIII study of AMN107, a novel aminopyrimidine inhibitor of bcr-abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph plus) acute lymphocytic leukemia (ALL),” Blood, vol. 104, No. 11, Part 1, pp. 10A-11A (2004).
Martinelli et al., “Imatinib mesylate can induce complete molecular remission in FIP1L-PDGFR-a positive idiopathic hypereosinophilic syndrome,” Haematologica, vol. 89, No. 2, pp. 236-237 (2004).
Cools et al., “The FLP1L1-PDGFRALPHA Kinase in Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia,” Current Opinion in Hematology, vol. 11, No. 1, p. 51-57, (2004).
Gunby et al., “Sensitivity to imatinib by low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia,” Haematologica, vol. 88, No. 4, pp. 408-415 (2003).
Fabbro Doriano
Manley Paul W.
Mestan Jürgen
Balasubramanian Venkataraman
Mulkeen Matthew
Novartis AG
LandOfFree
Pyrimidylaminobenzamide derivatives for hypereosinophilic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidylaminobenzamide derivatives for hypereosinophilic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidylaminobenzamide derivatives for hypereosinophilic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164830